Each winter, a familiar virus moves through New Zealand's youngest children with quiet certainty, filling hospital wards and exhausting families in ways that have long been accepted as inevitable. Two health unions are now challenging that acceptance, arguing that RSV — responsible for 2,000 pediatric hospitalizations and $25 million in annual costs — belongs in the same category of preventable harm as influenza and COVID-19. The vaccines exist, the infrastructure exists, and a neighboring country has already acted; what remains is a decision about whether prevention is worth prioritizing befo
Health Unions Push for Fast-Track RSV Vaccine Approval and Funding in NZ
RSV causes 2,000 hospitalizations annually of children under 5 in New Zealand, representing significant morbidity and healthcare burden for vulnerable infants.
We should be doing everything we can to reduce that pressure.
Mark
Why is RSV suddenly a priority now? The virus has been around for years.
Mimi
It hasn't been sudden—the virus has always been there, hospitalizing thousands of children every winter. What's changed is that effective vaccines now exist and are being used elsewhere. The unions are saying we have a tool we didn't have before, and we should use it.
Mark
But Pharmac must have reasons for not funding it yet. Cost? Efficacy concerns?
Mimi
The vaccines are approved in Australia, so efficacy isn't the question. It's likely a matter of process and priority. Pharmac evaluates hundreds of medicines. RSV vaccines are in the queue, but the unions are arguing they should jump the queue because of the scale of the problem—2,000 hospitalizations a year, $25 million in costs.
Mark
Is this really about hospital capacity, or is it about preventing suffering in children?
Mimi
Both. The unions frame it as a system problem—hospitals are under pressure—but the human reality is that children are getting seriously ill and their families are going through trauma. Preventing that is the point. The hospital pressure is just the visible consequence.
Mark
What would fast-track approval actually mean in practice?
Mimi
It would mean Medsafe and Pharmac working in parallel rather than sequentially, and Pharmac committing to fund the vaccine once it's approved, rather than making families wait months or years for a funding decision. It's the same model they used for COVID vaccines.
Mark
If this happens, who gets vaccinated first?
Mimi
The unions mention the most at-risk groups: elderly people, immunocompromised adults, pregnant women, and infants. But the real question is whether it becomes universal, like flu shots, or stays targeted to high-risk groups. That's a decision still to come.
Mark
What happens if Pharmac says no?
Mimi
Then children keep getting hospitalized at the current rate, the health system stays under pressure, and New Zealand falls further behind countries like Australia that have already made the decision. The unions are essentially saying that's an unacceptable outcome.
O Pulso
- Every winter, RSV fills roughly 2,000 hospital beds with children under five, draining $25 million from a health system already stretched to its limits.
- Two major health unions — representing nearly 9,000 doctors and allied health professionals — are demanding the Ministry of Health and Pharmac stop treating this annual crisis as unavoidable.
- Australia has already approved and funded RSV vaccines, while New Zealand's Medsafe reviews candidates and Pharmac has yet to commit a single dollar to coverage.
- Recent surveillance data from Auckland hospitals identified RSV as the second most common virus among respiratory admissions, with peak winter season still approaching.
- The unions are not asking for new infrastructure — flu and COVID programs already demonstrate the machinery works — they are asking for the political will to use it.
Each winter, a familiar virus moves through New Zealand's youngest children with quiet certainty, filling hospital wards and exhausting families in ways that have long been accepted as inevitable. Two health unions are now challenging that acceptance, arguing that RSV — responsible for 2,000 pediatric hospitalizations and $25 million in annual costs — belongs in the same category of preventable harm as influenza and COVID-19. The vaccines exist, the infrastructure exists, and a neighboring country has already acted; what remains is a decision about whether prevention is worth prioritizing before the season arrives, not after.
Every winter, RSV moves through New Zealand's youngest children with predictable force, sending roughly 2,000 under-fives into hospital beds and costing the health system an estimated $25 million. Those wards fill. Those parents wait. And the strain on public hospitals compounds what is already a system under pressure.
Two unions have decided the waiting is over. The New Zealand Resident Doctors' Association and the APEX Union — together representing around 9,000 health professionals — are calling on the Ministry of Health and Pharmac to fast-track RSV vaccine approval, funding, and distribution. Their argument is simple: the vaccines exist, they work, and Australia has already deployed them. What New Zealand lacks is not the tools but the decision to use them.
Dr. Deborah Powell, National Secretary of both unions, framed the push in terms of system capacity. Public hospitals are under immense pressure, she said, and every preventable admission is a failure of foresight. Recent surveillance data from Auckland reinforced the urgency — RSV ranked as the second most common virus detected among people hospitalized for respiratory illness over the past month, with winter still deepening.
The unions are not asking for something new. National immunization programs for influenza and COVID-19 already demonstrate that coordinated, funded rollouts are possible. The precedent is set. The infrastructure exists. What remains is the will to treat RSV as the public health priority the data says it is — before peak season arrives, not after the wards are already full.
Every winter, respiratory syncytial virus sweeps through New Zealand's youngest children with predictable force. The virus sends roughly 2,000 children under five into hospital beds each year—a cascade of admissions that costs the health system an estimated $25 million annually. Those beds are occupied. Those parents are frightened. Those wards are full. And yet, as the virus circulates and hospitalizations mount, New Zealand's public hospitals remain under strain that preventive medicine could help ease.
Two health unions have decided the time for waiting is over. The New Zealand Resident Doctors' Association, which represents 3,000 resident doctors, and the APEX Union, representing 6,000 allied, scientific, and technical health professionals, are pushing the Ministry of Health and Pharmac to move quickly on RSV vaccines. They want expedited approval, funding, procurement, and distribution—the same machinery that rolls out flu shots and COVID vaccines each year, but applied now to a virus that has been circulating in hospitals and homes for decades.
The case is straightforward. RSV vaccines exist. They work. Australia has already approved and funded them. In New Zealand, Medsafe has several candidates under consideration, but Pharmac—the agency that decides which medicines the public health system will pay for—has not yet committed funding. The vaccines would protect the most vulnerable: elderly people, immunocompromised adults, pregnant women, and infants. Dr. Deborah Powell, National Secretary of both unions, framed the argument in terms of system capacity. "Our public hospitals are under immense pressure," she said. "We should be doing everything we can to reduce that pressure." The logic mirrors the reasoning behind any preventive health program: stop people from getting sick, and you stop them from needing a hospital bed.
Recent surveillance data underscores the point. Over the past month, PHF Science tracked RSV across Auckland's hospital system and found it to be the second most common virus detected among people admitted for respiratory illness. Winter is coming. The virus will spread. Children will get sick. Some will need oxygen, monitoring, intravenous fluids. Some will need intensive care. All of this is preventable if a vaccine is available and accessible before the season arrives.
The unions are not asking for something unprecedented. New Zealand already runs national immunization programs for influenza and COVID-19. The infrastructure exists. The precedent is set. What is missing is the decision to treat RSV the same way—as a public health priority worthy of coordinated, funded action. Powell put it plainly: "Keeping our health system together requires more than just hoping for the best. We need to proactively adopt all the tools we can to help reduce the burden of disease on our people and our system. Making RSV vaccinations available and free would be one important means to do this."
The question now is whether the Ministry of Health and Pharmac will move with the urgency the unions are demanding. Winter does not wait for bureaucratic processes to complete. Every week of delay is another week closer to peak season, another week in which vulnerable children remain unprotected. The unions have made their case. The data supports it. The vaccines are ready. What remains is the decision to deploy them.
Citações Notáveis
Our public hospitals are under immense pressure; we should be doing everything we can to reduce that pressure.— Dr. Deborah Powell, National Secretary of NZRDA and APEX
Keeping our health system together requires more than just hoping for the best. We need to proactively adopt all the tools we can to help reduce the burden of disease on our people and our system.— Dr. Deborah Powell
Quer a matéria completa?
Leia o original em Scoop - New Zealand News ↗
Health & Medicine